MedTest Holdings, Canton, Mich, has changed its corporate name to MedText Dx.

According to the company, the new MedTest Dx nomenclature reflects a rapidly growing business that serves the decentralized testing community through its comprehensive portfolio of diagnostic products and services that seamlessly integrate screening instruments, reagent development and manufacturing, toxicology confirmation products, and world-class service.


Wayne Brinster, CEO, MedTest Dx.

The company now known as MedTest Dx began with the 2011 purchase of Polymedco’s chemistry product line. The addition of Pointe Scientific brought high quality reagents, calibrators and controls, enzyme immunoassays, and specialty assays to the new firm.

The acquisition of Clinitox Diagostix added capabilities in drugs of abuse testing, enabling confirmation tests via LC/MS instrumentation, reagents, and consumables. Finally, by acquiring Medical Laboratories Solutions, MedTest Dx gained a highly regarded clinical diagnostic laboratory service offering to complement and support the company’s instruments, assays, and reagents.

“Our goal in integrating these leading diagnostic brands to create MedTest Dx was to offer a comprehensive high-quality solution that enables our clinical lab customers to provide decentralized clinical testing services efficiently and cost-effectively,” says Wayne Brinster, CEO at MedTest Dx. “We are proud of the breadth and excellence of our integrated mix of products and services and of the customer focus that informs everything we do.”

To learn more, visit MedTest Dx.